Tumour response and safety of cetuximab in a window pre-operative study in patients with squamous cell carcinoma of the head and neck.

111In-cetuximab-F(ab')2 SPECT and 18F-FDG PET for prediction and response monitoring of combined-modality treatment of human head and neck carcinomas in a mouse model

Dijk, L.K. van
Boerman, O.C.
Franssen, G.M.
Kaanders, J.H.A.M.
Bussink, J.

January 2015

Item does not contain fulltextTreatment of head and neck squamous cell carcinomas with radiotherapy ...

Evaluation of individual sensitivity of head and neck squamous cell carcinoma to cetuximab by short-term culture of tumor slices

Peria, Marine
Donnadieu, Jerome
Racz, Caroline
Ikoli, Jean-Fortune
Galmiche, Antoine
Chauffert, Bruno
Page, Cyril

January 2016

International audienceBackground. Cetuximab is a targeted therapy with demonstrated efficacy in the ...

Dynamic contrast-enhanced computed tomography to assess early activity of cetuximab in squamous cell carcinoma of the head and neck

Schmitz, Sandra
Rommel, Denis
Michoux, Nicolas
Lhommel, Renaud
Hanin, François-Xavier
Duprez, Thierry
Machiels, Jean-Pascal

January 2015

BACKGROUND: Cetuximab, a monoclonal antibody targeting the Epidermal Growth Factor Receptor (EGFR), ...

Safety, molecular and imaging responses to cetuximab administered in a window pre-operative study in squamous cell carcinoma of the head and neck(SCCHN)

Schmitz, Sandra
Hamoir, Marc
Reychler, Hervé
Magremanne, Michèle
Weynand, Birgit
Lhommel, Renaud
Hanin, François-Xavier
Lonneux, Max
Rommel, Denis
Michoux, Nicolas
Duprez, Thierry
Machiels, Jean-Pascal
ASCO Annual Meeting

January 2012

Background: Only a minority of SCCHN pts benefits from anti-EGFR mAbs. Trials with pre- and post-the...

Modulation of the peritumoral microenvironment by cetuximab:a window pre-operative study in patients with squamous cell carcinoma of the head and neck (SCCHN)

Schmitz, Sandra
Hamoir, Marc
Reychler, Hervé
Magremanne, Michèle
Weynand, Birgit
Lhommel, Renaud
Hanin, François-Xavier
Rommel, Denis
Michoux, Nicolas
Machiels, Jean-Pascal
The 37th ESMO Congress

January 2012

Background : Only a subset of SCCHN pts benefits from anti-EGFR mAbs. Trials with pre- and post-ther...

2'-deoxy-2'-[18F] fluoro-D-glucose positron emission tomography, diffusion-weighted magnetic resonance imaging, and choline spectroscopy to predict the activity of cetuximab in tumor xenografts derived from patients with squamous cell carcinoma of the head and neck.

Mignion, Lionel
Schmitz, Sandra
Michoux, Nicolas
Caignet, Xavier
Goebbels, Rose-Marie
Bol, Anne
Neveu, Marie-Aline C
Grégoire, Vincent
Duprez, Thierry
Lhommel, Renaud
Amant, Fréderic
Hermans, Els
Jordan, Benedicte F
Machiels, Jean-Pascal

June 2018

We investigated changes on 2'-deoxy-2'-[18F]fluoro-D-glucose positron emission tomography (18FDG-PET...

Cetuximab-F(ab')2-SPECT and FDG-PET for prediction and response monitoring of combined modality treatment of human head and neck carcinomas in a mouse model

Dijk, L.K. van
Boerman, O.C.
Franssen, G.M.
Kaanders, J.H.A.M.
Bussink, J.

January 2015

Item does not contain fulltextTreatment of head and neck squamous cell carcinomas (HNSCC) with radio...

Early Response Monitoring with 18F-FDG PET and Cetuximab-F(ab')2-SPECT After Radiotherapy of Human Head and Neck Squamous Cell Carcinomas in a Mouse Model

Dijk, L.K. van
Boerman, O.C.
Franssen, G.M.
Lok, J.
Kaanders, J.H.A.M.
Bussink, J.

January 2014

Only a subset of patients with head and neck squamous cell carcinomas (HNSCCs) benefit from radiothe...

18F-FLT PET changes during radiotherapy combined with cetuximab in head and neck squamous cell carcinoma patients

Hoeben, B.A.W.
Troost, E.G.C.
Bussink, J.
Herpen, C.M.L. van
Oyen, W.J.G.
Kaanders, J.H.A.M.

January 2014

Item does not contain fulltextAIM: Early treatment response of head and neck cancer to radiotherapy ...

F-18-FLT PET changes during radiotherapy combined with cetuximab in head and neck squamous cell carcinoma patients

Hoeben, B. A. W.
Troost, E. G. C.
Bussink, J.
van Herpen, C. M. L.
Oyen, W. J. G.
Kaanders, J. H. A. M.

January 2014

Aim: Early treatment response of head and neck cancer to radiotherapy concomitant with cetuximab was...

PET imaging of zirconium-89 labelled cetuximab: A phase I trial in patients with head and neck and lung cancer

van Loon, Judith
Even, Aniek J G
Aerts, Hugo J W L
Öllers, Michel
Hoebers, Frank
van Elmpt, Wouter
Dubois, Ludwig
Dingemans, Anne-Marie C
Lalisang, Roy I
Kempers, Pascal
Brans, Boudewijn
Winnepenninckx, Véronique
Speel, Ernst-Jan
Thunnissen, Eric
Smits, Kim M
Boellaard, Ronald
Vugts, Danielle J
De Ruysscher, Dirk
Lambin, Philippe

December 2016

BACKGROUND AND PURPOSE: PET imaging of cetuximab uptake may help selecting cancer patients with the ...

Quantitative assessment of Zirconium-89 labeled cetuximab using PET/CT imaging in patients with advanced head and neck cancer: A theragnostic approach

Even, Aniek J.G.
Hamming-Vrieze, Olga
van Elmpt, Wouter
Winnepenninckx, Véronique J.L.
Heukelom, Jolien
Tesselaar, Margot E.T.
Vogel, Wouter V.
Hoeben, Ann
Zegers, Catharina M.L.
Vugts, Daniëlle J.
van Dongen, Guus A.M.S.
Bartelink, Harry
Mottaghy, Felix M.
Hoebers, Frank
Lambin, Philippe

January 2017

Biomarkers predicting treatment response to the monoclonal antibody cetuximab in locally advanced he...

Early prediction of response to cetuximab and radiotherapy by FDG-PET/CT for the treatment of a locoregionally advanced squamous cell carcinoma of the hypopharynx

Mindaugas Grybauskas

September 2014

Cetuximab (CTX) is used for the concurrent treatment with radiotherapy (RT) in squamous cell carcino...

Quantitative assessment of Zirconium-89 labeled cetuximab using PET/CT imaging in patients with advanced head and neck cancer: a theragnostic approach

Even, Aniek J. G.
Hamming-Vrieze, Olga
van Elmpt, Wouter
Winnepenninckx, Veronique J. L.
Heukelom, Jolien
Tesselaar, Margot E. T.
Vogel, Wouter V.
Hoeben, Ann
Zegers, Catharina M. L.
Vugts, Danielle J.
van Dongen, Guus A. M. S.
Bartelink, Harry
Mottaghy, Felix M.
Hoebers, Frank
Lambin, Philippe

January 2017

Biomarkers predicting treatment response to the monoclonal antibody cetuximab in locally advanced he...

111In-Cetuximab-F(ab9)2 SPECTand 18F-FDG PET for Prediction and Response Monitoring of Combined-Modality Treatment of Human Head and Neck Carcinomas in a Mouse Model

Laura K. Van Dijk
Otto C. Boerman
Gerben M. Franssen
Johannes H. A. M. Ka
Johan Bussink

September 2016

Treatment of head and neck squamous cell carcinomas with radio-therapy and the epidermal growth fact...

111In-cetuximab-F(ab')2 SPECT and 18F-FDG PET for prediction and response monitoring of combined-modality treatment of human head and neck carcinomas in a mouse model

Dijk, L.K. van
Boerman, O.C.
Franssen, G.M.
Kaanders, J.H.A.M.
Bussink, J.

January 2015

Item does not contain fulltextTreatment of head and neck squamous cell carcinomas with radiotherapy ...

Evaluation of individual sensitivity of head and neck squamous cell carcinoma to cetuximab by short-term culture of tumor slices

Peria, Marine
Donnadieu, Jerome
Racz, Caroline
Ikoli, Jean-Fortune
Galmiche, Antoine
Chauffert, Bruno
Page, Cyril

January 2016

International audienceBackground. Cetuximab is a targeted therapy with demonstrated efficacy in the ...

Dynamic contrast-enhanced computed tomography to assess early activity of cetuximab in squamous cell carcinoma of the head and neck

Schmitz, Sandra
Rommel, Denis
Michoux, Nicolas
Lhommel, Renaud
Hanin, François-Xavier
Duprez, Thierry
Machiels, Jean-Pascal

January 2015

BACKGROUND: Cetuximab, a monoclonal antibody targeting the Epidermal Growth Factor Receptor (EGFR), ...

Safety, molecular and imaging responses to cetuximab administered in a window pre-operative study in squamous cell carcinoma of the head and neck(SCCHN)

Schmitz, Sandra
Hamoir, Marc
Reychler, Hervé
Magremanne, Michèle
Weynand, Birgit
Lhommel, Renaud
Hanin, François-Xavier
Lonneux, Max
Rommel, Denis
Michoux, Nicolas
Duprez, Thierry
Machiels, Jean-Pascal
ASCO Annual Meeting

January 2012

Background: Only a minority of SCCHN pts benefits from anti-EGFR mAbs. Trials with pre- and post-the...

Modulation of the peritumoral microenvironment by cetuximab:a window pre-operative study in patients with squamous cell carcinoma of the head and neck (SCCHN)

Schmitz, Sandra
Hamoir, Marc
Reychler, Hervé
Magremanne, Michèle
Weynand, Birgit
Lhommel, Renaud
Hanin, François-Xavier
Rommel, Denis
Michoux, Nicolas
Machiels, Jean-Pascal
The 37th ESMO Congress

January 2012

Background : Only a subset of SCCHN pts benefits from anti-EGFR mAbs. Trials with pre- and post-ther...

2'-deoxy-2'-[18F] fluoro-D-glucose positron emission tomography, diffusion-weighted magnetic resonance imaging, and choline spectroscopy to predict the activity of cetuximab in tumor xenografts derived from patients with squamous cell carcinoma of the head and neck.

Mignion, Lionel
Schmitz, Sandra
Michoux, Nicolas
Caignet, Xavier
Goebbels, Rose-Marie
Bol, Anne
Neveu, Marie-Aline C
Grégoire, Vincent
Duprez, Thierry
Lhommel, Renaud
Amant, Fréderic
Hermans, Els
Jordan, Benedicte F
Machiels, Jean-Pascal

June 2018

We investigated changes on 2'-deoxy-2'-[18F]fluoro-D-glucose positron emission tomography (18FDG-PET...

Cetuximab-F(ab')2-SPECT and FDG-PET for prediction and response monitoring of combined modality treatment of human head and neck carcinomas in a mouse model

Dijk, L.K. van
Boerman, O.C.
Franssen, G.M.
Kaanders, J.H.A.M.
Bussink, J.

January 2015

Item does not contain fulltextTreatment of head and neck squamous cell carcinomas (HNSCC) with radio...

Early Response Monitoring with 18F-FDG PET and Cetuximab-F(ab')2-SPECT After Radiotherapy of Human Head and Neck Squamous Cell Carcinomas in a Mouse Model

Dijk, L.K. van
Boerman, O.C.
Franssen, G.M.
Lok, J.
Kaanders, J.H.A.M.
Bussink, J.

January 2014

Only a subset of patients with head and neck squamous cell carcinomas (HNSCCs) benefit from radiothe...

18F-FLT PET changes during radiotherapy combined with cetuximab in head and neck squamous cell carcinoma patients

Hoeben, B.A.W.
Troost, E.G.C.
Bussink, J.
Herpen, C.M.L. van
Oyen, W.J.G.
Kaanders, J.H.A.M.

January 2014

Item does not contain fulltextAIM: Early treatment response of head and neck cancer to radiotherapy ...

F-18-FLT PET changes during radiotherapy combined with cetuximab in head and neck squamous cell carcinoma patients

Hoeben, B. A. W.
Troost, E. G. C.
Bussink, J.
van Herpen, C. M. L.
Oyen, W. J. G.
Kaanders, J. H. A. M.

January 2014

Aim: Early treatment response of head and neck cancer to radiotherapy concomitant with cetuximab was...

PET imaging of zirconium-89 labelled cetuximab: A phase I trial in patients with head and neck and lung cancer

van Loon, Judith
Even, Aniek J G
Aerts, Hugo J W L
Öllers, Michel
Hoebers, Frank
van Elmpt, Wouter
Dubois, Ludwig
Dingemans, Anne-Marie C
Lalisang, Roy I
Kempers, Pascal
Brans, Boudewijn
Winnepenninckx, Véronique
Speel, Ernst-Jan
Thunnissen, Eric
Smits, Kim M
Boellaard, Ronald
Vugts, Danielle J
De Ruysscher, Dirk
Lambin, Philippe

December 2016

BACKGROUND AND PURPOSE: PET imaging of cetuximab uptake may help selecting cancer patients with the ...

Quantitative assessment of Zirconium-89 labeled cetuximab using PET/CT imaging in patients with advanced head and neck cancer: A theragnostic approach

Even, Aniek J.G.
Hamming-Vrieze, Olga
van Elmpt, Wouter
Winnepenninckx, Véronique J.L.
Heukelom, Jolien
Tesselaar, Margot E.T.
Vogel, Wouter V.
Hoeben, Ann
Zegers, Catharina M.L.
Vugts, Daniëlle J.
van Dongen, Guus A.M.S.
Bartelink, Harry
Mottaghy, Felix M.
Hoebers, Frank
Lambin, Philippe

January 2017

Biomarkers predicting treatment response to the monoclonal antibody cetuximab in locally advanced he...

Early prediction of response to cetuximab and radiotherapy by FDG-PET/CT for the treatment of a locoregionally advanced squamous cell carcinoma of the hypopharynx

Mindaugas Grybauskas

September 2014

Cetuximab (CTX) is used for the concurrent treatment with radiotherapy (RT) in squamous cell carcino...

Quantitative assessment of Zirconium-89 labeled cetuximab using PET/CT imaging in patients with advanced head and neck cancer: a theragnostic approach

Even, Aniek J. G.
Hamming-Vrieze, Olga
van Elmpt, Wouter
Winnepenninckx, Veronique J. L.
Heukelom, Jolien
Tesselaar, Margot E. T.
Vogel, Wouter V.
Hoeben, Ann
Zegers, Catharina M. L.
Vugts, Danielle J.
van Dongen, Guus A. M. S.
Bartelink, Harry
Mottaghy, Felix M.
Hoebers, Frank
Lambin, Philippe

January 2017

Biomarkers predicting treatment response to the monoclonal antibody cetuximab in locally advanced he...

111In-Cetuximab-F(ab9)2 SPECTand 18F-FDG PET for Prediction and Response Monitoring of Combined-Modality Treatment of Human Head and Neck Carcinomas in a Mouse Model

Laura K. Van Dijk
Otto C. Boerman
Gerben M. Franssen
Johannes H. A. M. Ka
Johan Bussink

September 2016

Treatment of head and neck squamous cell carcinomas with radio-therapy and the epidermal growth fact...

111In-cetuximab-F(ab')2 SPECT and 18F-FDG PET for prediction and response monitoring of combined-modality treatment of human head and neck carcinomas in a mouse model

Dijk, L.K. van
Boerman, O.C.
Franssen, G.M.
Kaanders, J.H.A.M.
Bussink, J.

January 2015

Item does not contain fulltextTreatment of head and neck squamous cell carcinomas with radiotherapy ...

Evaluation of individual sensitivity of head and neck squamous cell carcinoma to cetuximab by short-term culture of tumor slices

Peria, Marine
Donnadieu, Jerome
Racz, Caroline
Ikoli, Jean-Fortune
Galmiche, Antoine
Chauffert, Bruno
Page, Cyril

January 2016

International audienceBackground. Cetuximab is a targeted therapy with demonstrated efficacy in the ...

Dynamic contrast-enhanced computed tomography to assess early activity of cetuximab in squamous cell carcinoma of the head and neck

Schmitz, Sandra
Rommel, Denis
Michoux, Nicolas
Lhommel, Renaud
Hanin, François-Xavier
Duprez, Thierry
Machiels, Jean-Pascal

January 2015

BACKGROUND: Cetuximab, a monoclonal antibody targeting the Epidermal Growth Factor Receptor (EGFR), ...

Tumour response and safety of cetuximab in a window pre-operative study in patients with squamous cell carcinoma of the head and neck.

Abstract

Extracted data

Tumour response and safety of cetuximab in a window pre-operative study in patients with squamous cell carcinoma of the head and neck.

Abstract

Extracted data

Related items

Related items